Aynalem SB, Zeleke AJ. Prevalence of Diabetes Mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman Town, Southwest Ethiopia, 2016: a cross sectional study. Int J Endocrinol. 2018;2018:9317987. https://doi.org/10.1155/2018/9317987.
Article PubMed PubMed Central Google Scholar
Diabetes [Internet]. [cited 2023 Dec 19]. Available from: https://www.who.int/health-topics/diabetes#tab=tab_1. Accessed 11 Dec 2023
Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9:525–44. https://doi.org/10.1016/S2213-8587(21)00113-3.
Article CAS PubMed Google Scholar
Ng E, Shaw JE, Wood A, Maple-Brown LJ, Hare MJ. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes. Aust J Gen Pract. 2022;51:513–8. https://doi.org/10.31128/AJGP-07-21-6057.
Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021;12:721135. https://doi.org/10.3389/fendo.2021.721135.
Pratama KG, Tandarto K, Hengky A. Weight loss effect of sodium-glucose, cotransporter-2 (sglt2) inhibitors in patients with obesity without diabetes: a systematic review. Acta Endocrinol (Buchar). 2022;18(2):216–24. https://doi.org/10.4183/aeb.2022.216.
Article CAS PubMed PubMed Central Google Scholar
Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, et al. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care. 2022;10:e002207.
Article PubMed PubMed Central Google Scholar
Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, et al. Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study. Diabetes Obes Metab. 2019;21:2429–39. https://doi.org/10.1111/dom.13824.
Article CAS PubMed PubMed Central Google Scholar
Yoon K, Kang J, Kwon SC, Trautmann ME, Hompesch M, Stewart J, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22:1292–301. https://doi.org/10.1111/dom.14032.
Article CAS PubMed PubMed Central Google Scholar
Abdelhaleem IA, Abd-Elhamied MA, Morsi AE, Kenawy S. Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2022;24:555–60. https://doi.org/10.1111/dom.14602.
Article CAS PubMed Google Scholar
Escobar J, Monday O, Vemoori Y, et al. Safety and efficacy of Efpeglenatide in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Cureus. 2023;15(9):e45927. https://doi.org/10.7759/cureus.45927.
Ansari HUH, Qazi SU, Sajid F, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024;30(2):160–71. https://doi.org/10.1016/j.eprac.2023.11.007.
Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:1–12. https://doi.org/10.1155/2018/4020492.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89. https://doi.org/10.1136/bmj.n71.
ElSayed NA, Aleppo G, Aroda VR et al. 2. Classification and diagnosis of diabetes: Standards of care in diabetes-2023 [published correction appears in Diabetes Care. 2023;:] [published correction appears in Diabetes Care. 2023;46(9):1715]. Diabetes Care. 2023;46(Suppl 1):S19-S40. https://doi.org/10.2337/dc23-S002
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928-5928. https://doi.org/10.1136/bmj.d5928.
Article PubMed PubMed Central Google Scholar
Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2023 Dec 2]. Available from: https://training.cochrane.org/handbook
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. https://doi.org/10.1111/j.0006-341x.2000.00455.x.
Article CAS PubMed Google Scholar
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269.
Article CAS PubMed Google Scholar
Gerstein HC, Li Z, Ramasundarahettige C, Baek S, Branch KRH, Del Prato S, et al. Exploring the relationship between Efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial. Circulation. 2023;147:1004–13. https://doi.org/10.1161/CIRCULATIONAHA.122.063716.
Article CAS PubMed Google Scholar
Del Prato S, Kang J, Trautmann ME, Stewart J, Sorli CH, Derwahl M, et al. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Diabetes Obes Metab. 2020;22:1176–86. https://doi.org/10.1111/dom.14020.
Article CAS PubMed PubMed Central Google Scholar
Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, et al. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase ib study. BMJ Open Diabetes Res Care. 2021;9:e002208.
Article PubMed PubMed Central Google Scholar
Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, et al. Once-weekly Efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to Liraglutide. Diabetes Care. 2019;42:1733–41. https://doi.org/10.2337/dc18-2648.
Article CAS PubMed Google Scholar
Aroda VR, Frias JP, Ji L, Niemoeller E, Nguyên-Pascal M-L, Denkel K, et al. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials. Diabetes Obes Metab. 2023;25:2084–95. https://doi.org/10.1111/dom.15079.
Article CAS PubMed Google Scholar
Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al. Efficacy and safety of once-weekly Efpeglenatide Monotherapy Versus Placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45:1592–600. https://doi.org/10.2337/dc21-2656.
Article CAS PubMed PubMed Central Google Scholar
Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose Cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145:565–74. https://doi.org/10.1161/CIRCULATIONAHA.121.057934.
Article CAS PubMed Google Scholar
McCormack JP, Allan GM, Virani AS. Is bigger better? An argument for very low starting doses. CMAJ. 2011;183(1):65–9. https://doi.org/10.1503/cmaj.091481.
Article PubMed PubMed Central Google Scholar
Tariq MA, Amin H, Shurjeel Q, Gang A, Mohiuddin A. Gastrointestinal adverse events of semaglutide in patients with overweight or obesity. Eur J Intern Med. 2022;106:138–9. https://doi.org/10.1016/j.ejim.2022.08.015.
Article CAS PubMed Google Scholar
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/NEJMoa2307563.
留言 (0)